David R. Wise, MD, PhD, discusses the potential for pasritamig combined with docetaxel to improve outcomes in patients with mCRPC. Wise is a genitourinary medical oncologist at NYU Langone Health and ...

The management of testicular cancer continues to evolve, with advances in diagnostics, risk stratification, and multimodal treatment shaping contemporary clinical practice. At the 41st Annual Congress ...

"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.

Experts recommend removing unsupported prostate cancer warnings from TRT labels and aligning indications with professional guidelines. Testosterone's Schedule III classification creates barriers to ...

"Based on the code description, we recommend basing the code selection on the documentation and the effort required to complete the service, and not the number of foreign bodies removed from the ...

Panelists discuss how real-world comparisons of apalutamide and enzalutamide suggest survival trends influenced by tolerability, adherence, and patient selection rather than intrinsic drug differences ...

ORIC-944 demonstrated significant anti-tumor activity and tolerability in combination with ARPIs in mCRPC patients. The phase 1b trial showed notable PSA and ctDNA reductions across all ORIC-944 dose ...

The BioProtect Balloon Spacer significantly preserves bowel, urinary, and sexual quality of life in prostate cancer patients undergoing radiation therapy over four years. The study showed ...

The Virtuoso Surgical Robotic System received FDA breakthrough designation for bladder lesion removal, enabling expedited development and review processes. En bloc resection improves cancer staging ...

The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...

The STRIKE-001 trial evaluates KTX-2001, an NSD2 inhibitor, for mCRPC, with FDA clearance and collaboration with Bayer for darolutamide supply. The trial, managed by PCCTC, will enroll 144 patients, ...

Enzalutamide plus ADT significantly reduced the risk of radiographic progression or death and castration resistance compared to darolutamide plus ADT in mHSPC patients. The MAIC analysis provided a ...